Dipna Pharmachem Ltd
₹ 8.15
-0.12%
04 Jul
4:01 p.m.
About
Incorporated in 2011, Dipna Pharmachem Limited is engaged in the trading and distribution of a wide range of pharmaceutical raw materials including APIs, Excipient, and chemical formulation products across India.[1]
Key Points
- Market Cap ₹ 19.6 Cr.
- Current Price ₹ 8.15
- High / Low ₹ 24.1 / 7.51
- Stock P/E 18.0
- Book Value ₹ 15.6
- Dividend Yield 0.00 %
- ROCE 8.49 %
- ROE 4.47 %
- Face Value ₹ 10.0
Pros
- Stock is trading at 0.52 times its book value
- Debtor days have improved from 101 to 63.4 days.
Cons
- Though the company is reporting repeated profits, it is not paying out dividend
- Company has low interest coverage ratio.
- Promoter holding is low: 9.98%
- Company has a low return on equity of 8.22% over last 3 years.
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Loading peers table ...
Half Yearly Results
Figures in Rs. Crores
Profit & Loss
Figures in Rs. Crores
Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
---|---|---|---|---|---|---|---|
17 | 20 | 30 | 31 | 73 | 100 | 164 | |
16 | 20 | 30 | 31 | 71 | 98 | 161 | |
Operating Profit | 0 | 0 | 0 | 0 | 2 | 2 | 3 |
OPM % | 2% | 2% | 1% | 1% | 3% | 2% | 2% |
0 | 0 | 0 | 0 | 0 | 0 | 0 | |
Interest | 0 | 0 | 0 | 0 | 1 | 1 | 2 |
Depreciation | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Profit before tax | 0 | 0 | 0 | 0 | 2 | 1 | 1 |
Tax % | 14% | 40% | 0% | 60% | 26% | 34% | 24% |
0 | 0 | 0 | 0 | 1 | 1 | 1 | |
EPS in Rs | 6.00 | 3.00 | 6.00 | 2.00 | 117.00 | 0.37 | 0.45 |
Dividend Payout % | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
Compounded Sales Growth | |
---|---|
10 Years: | % |
5 Years: | 52% |
3 Years: | 75% |
TTM: | 64% |
Compounded Profit Growth | |
---|---|
10 Years: | % |
5 Years: | 105% |
3 Years: | 279% |
TTM: | 20% |
Stock Price CAGR | |
---|---|
10 Years: | % |
5 Years: | % |
3 Years: | % |
1 Year: | -55% |
Return on Equity | |
---|---|
10 Years: | % |
5 Years: | 8% |
3 Years: | 8% |
Last Year: | 4% |
Balance Sheet
Figures in Rs. Crores
Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
---|---|---|---|---|---|---|---|
Equity Capital | 0 | 0 | 0 | 0 | 0 | 12 | 24 |
Reserves | 0 | 0 | 1 | 1 | 2 | 12 | 13 |
5 | 6 | 10 | 12 | 10 | 16 | 19 | |
6 | 8 | 8 | 12 | 24 | 37 | 76 | |
Total Liabilities | 11 | 14 | 18 | 25 | 36 | 78 | 133 |
0 | 0 | 0 | 0 | 0 | 0 | 0 | |
CWIP | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
11 | 14 | 18 | 25 | 36 | 78 | 133 | |
Total Assets | 11 | 14 | 18 | 25 | 36 | 78 | 133 |
Cash Flows
Figures in Rs. Crores
Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
---|---|---|---|---|---|---|---|
-3 | -2 | 3 | -21 | -5 | |||
0 | 0 | -0 | -0 | -0 | |||
3 | 2 | -3 | 26 | 14 | |||
Net Cash Flow | 0 | 0 | -0 | 5 | 8 |
Ratios
Figures in Rs. Crores
Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
---|---|---|---|---|---|---|---|
Debtor Days | 132 | 160 | 134 | 176 | 135 | 104 | |
Inventory Days | 112 | 66 | 70 | 89 | 34 | 72 | |
Days Payable | 142 | 148 | 105 | 145 | 123 | 139 | |
Cash Conversion Cycle | 103 | 78 | 99 | 120 | 46 | 38 | |
Working Capital Days | 116 | 114 | 119 | 150 | 59 | 126 | |
ROCE % | 8% | 5% | 3% | 17% | 9% |
Documents
Announcements
- Board Meeting Outcome for Outcome Of Board Meeting Held Today I.E. On 12Th June, 2024 12 Jun
- Submission Of Audited Financial Results For The Half Year And Year Ended On 31St March, 2024 Along With Auditor'S Report 12 Jun
- Board Meeting Intimation for Intimation Of Board Meeting To Be Held On Wednesday, 12Th June, 2024 10 Jun
- Board Meeting Outcome for Outcome Of Board Meeting Held On 6Th May, 2024 6 May
- Board Meeting Intimation for Re-Schedule Of Board Meeting Held Today I.E. 2Nd May, 2024 2 May
Business Area[1] Dipna Pharmachem Ltd. (DPL) is engaged in trading and distribution of pharmaceutical raw materials such as APIs (Active Pharmaceutical Ingredients), excipients, and chemical formulation products. Presently its product portfolio comprises 61 AIPs and AIPs intermediates such as Cephalosporins, Cardiovascular, Anti - Bacteria, Quinolones, Veterinary, Anti - Virus, Anti - Inflammatory, Neuropsychiatry, Steroid Hormone, etc.